NASDAQ · STOCK
AbbVie
$248.02
52W $184.63 – $261.64
59/100
$406801.77T
121.6
0.28
Price History (6M)
Is ABBV Bullish or Bearish?
Mixed.
Innellis AI committee rates AbbVie (ABBV) Watch with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated July 13, 2026.
Executive Summary
7 analysts weighed in with 43% agreement on a neutral lean. Macro Analyst: Market regime is bullish (Bull market -- normal position sizing). Risk Analyst: High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario. Overall recommendation: WATCH.
Bull & Bear Case
Bull Case
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- MACD histogram is negative (-0.102) — bearish momentum.
- Fundamental score is weak (25.7/100) — poor financial health or expensive valuation.
AI Investment Committee
Committee Consensus
As of July 13, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Value Analyst
bearish
40
/ 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ ROE of 95.6% shows genuine earnings power backing the valuation
− P/E of 120.6 is expensive by classic value standards
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -13.5% YoY despite any revenue growth
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
33
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score strengthened from 54.4 to 59.4.
- Committee agreement increased modestly from 43% to 50%.
- Bullish support removed: 2 signal(s) disappeared.
- Bearish pressure eased: 6 signal(s) disappeared.
- Analyst(s) abstained: Value Analyst.
Analyst-level changes:
- Growth Analyst: score 44->58 (+14).
- Value Analyst abstained (was bearish at 40).
Comparing 2026-07-12 to 2026-07-13 (1 day apart).
Technical Analysis
RSI (14)
53.2
Neutral
MACD Histogram
-0.102
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.63
Inside Bands
Price vs Moving Averages
EMA 9
$249.71
Below
EMA 21
$241.83
Above
EMA 50
$230.08
Above
EMA 200
$218.73
Above
Fundamental Analysis
Valuation
33
Growth
58
Profitability
0
Financial Health
0
Cash Flow
37
Valuation
P/E Ratio
121.6×
P/B Ratio
16.00×
PEG Ratio
-9.22
Dividend Yield
0.03%
52W High
$261.64
52W Low
$184.63
Quality & Growth
ROE
-129.2%
ROA
3.1%
Gross Margin
70.7%
Operating Margin
27.6%
Revenue Growth YoY
—
Debt / Equity
2.65
AI Fundamental Assessment
P/E ratio of 121.6 (rich relative to a 15-40x range); Price-to-book of 16.0x; PEG ratio of -9.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -1.3%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 0.80 (tight short-term liquidity); Debt-to-equity of 2.65; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (11.76); Most recent quarter beat estimates by 0.2%; 4 consecutive earnings beats; EPS growth decelerating (+45.7% -> -2.2% QoQ); Analyst estimates rising over recent quarters
Key Risks
- MACD histogram is negative (-0.102) — bearish momentum.
- Fundamental score is weak (25.7/100) — poor financial health or expensive valuation.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full ABBV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile